The Rx Recap: July 6-11

Welcome to this week’s roundup of the most insightful and impactful articles from the sister publications of Dermatology Times, all under One MJH Life Sciences. Our network brings together expert perspectives, clinical advancements, and industry updates to keep clinicians informed and ahead of the curve. From cutting-edge treatments to practice management strategies, here’s a look at the top stories shaping the field of medicine.

Olanzapine/Triplet Cuts Chemo-Induced Nausea, Vomiting in Breast Cancer

This week Oncology Nursing News reported on a phase 3 trial has demonstrated that adding 5 mg of olanzapine to standard triplet antiemetic therapy significantly improves control of chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline plus cyclophosphamide-based regimens. Published in Lancet Oncology, the study showed notably higher complete response rates across both acute and delayed phases, without severe sedative side effects. With strong efficacy, manageable safety, and higher patient satisfaction, the findings support low-dose olanzapine as a valuable addition to antiemetic protocols in this high-risk population.

FDA-approved berdazimer gel, 10.3% launches to treat molluscum contagiosum

Pelthos Therapeutics has officially launched berdazimer (Zelsuvmi) topical gel, 10.3%, which according to Contemporary Pediatrics is the first FDA-approved at-home treatment for molluscum contagiosum in adults and children as young as one year. Backed by phase 3 trial data showing significant lesion clearance at 12 weeks, this nitric oxide–releasing gel offers a convenient alternative to in-office procedures for a common and often undertreated skin infection. Now available through retail and mail-order pharmacies, Zelsuvmi’s launch aims to close treatment gaps and meet an urgent need for accessible molluscum care.

Emerging Medication for mCRPC Gets FDA Fast Track Designation for Adjunctive Use with Radiation Therapy

Diagnostic Imaging reported that the FDA has granted Fast Track designation to TRE-515, an investigational oral deoxycytidine kinase inhibitor, for adjunctive use with Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in patients with metastatic castration-resistant prostate cancer (mCRPC). Developed by Trethera, TRE-515 is currently being studied as a monotherapy in a phase 1 trial, with early data suggesting promising anti-tumor activity and high tolerability. The designation aims to accelerate development of this novel combination approach for advanced prostate cancer treatment.

Telehealth gets a win in Trump’s tax package

While most health care leaders have sharply criticized the new tax legislation for its projected cuts to Medicaid and potential strain on hospitals, telehealth advocates are celebrating a major win: the permanent reinstatement of first-dollar coverage for telehealth services under High-Deductible Health Plan–Health Savings Accounts. Kyle Zebley of the American Telemedicine Association called the move a “good policy” that brings long-term certainty to millions of Americans, in a recent interview with Chief Healthcare Executive. Though broader concerns remain, especially around Medicaid access, the provision marks a rare and lasting federal commitment to virtual care.

Mid-Year Cannabis and Hemp Regulations Roundup

As cannabis regulation continues to evolve across the US, 2025 has already brought a wave of notable state-level developments, according to Cannabis Science and Technology. From Louisiana tightening restrictions on THC and CBD products, to California moving to cement emergency rules limiting hemp-derived items, states are taking varied approaches to access and safety. Meanwhile, Pennsylvania’s bid to legalize adult-use cannabis passed the House but failed in the Senate, and Virginia’s governor vetoed a medical cannabis bill, restricting delivery options. In Missouri, lawmakers advanced measures to limit sales of intoxicating hemp products outside dispensaries.Here's a look at the key cannabis policy changes so far this year.

Want to read more on specialty care, pharmacy, industry sciences, and more? Check out MJH Life Sciences full list of brands here.